Syndax Pharmaceuticals Inc (23)

Browse by Contract Category

Contracts

Form of Deferred Settlement Stock Unit Agreement under 2015 Omnibus Incentive Plan (Filed With SEC on March 12, 2021)
Underwriting Agreement, dated December 8, 2020, by and among the Company, Goldman Sachs & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC (Filed With SEC on December 9, 2020)
Amendment No. 12 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated May 12, 2020 (Filed With SEC on August 6, 2020)
Amendment No. 1 to License Agreement by and between the Company and UCB Biopharma Sprl, dated as of July 9, 2019 (Filed With SEC on November 7, 2019)
Executive Employment Agreement by and between the Company and Daphne Karydas, dated as of July 6, 2020 (Filed With SEC on November 5, 2020)
Form of Stock Unit Agreement under 2015 Omnibus Incentive Plan (Filed With SEC on August 6, 2020)
Loan and Security Agreement dated February 7, 2020 between Syndax Pharmaceuticals, Inc. and Hercules Capital, Inc (Filed With SEC on May 7, 2020)
Amended and Restated Executive Employment Agreement by and between the Company and Richard P. Shea, dated as of April 27, 2020 (Filed With SEC on May 7, 2020)
Amended and Restated Executive Employment Agreement by and between the Company and Michael L. Meyers, M.D., Ph.D., dated as of April 27, 2020 (Filed With SEC on May 7, 2020)
Amended and Restated Executive Employment Agreement by and between the Company and Michael A. Metzger, dated as of April 27, 2020 (Filed With SEC on May 7, 2020)
Amended and Restated Executive Employment Agreement by and between the Company and Briggs W. Morrison, M.D., dated as of April 27, 2020 (Filed With SEC on May 7, 2020)
Non-employee Director Compensation Policy, as amended, February 12, 2020 (Filed With SEC on May 7, 2020)
Underwriting Agreement, dated April 30, 2020, by and among the Company, Citigroup Global Markets Inc. and Cowen and Company, LLC (Filed With SEC on May 4, 2020)
Description of Capital Stock (Filed With SEC on March 5, 2020)
Purchase Agreement between the Company and the Purchasers, dated January 30, 2020 (Filed With SEC on February 4, 2020)
Form of Pre-Funded Warrant (Filed With SEC on February 4, 2020)
Amendment No. 11 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated July 1, 2019 (Filed With SEC on November 7, 2019)
Amendment No. 1 to License Agreement by and between the Company and Vitae Pharmaceuticals, Inc., dated as of January 25, 2019 (Filed With SEC on May 8, 2019)
Form of Series Warrant (Filed With SEC on March 29, 2019)
Purchase Agreement between the Company and the Purchaser, dated March 28, 2019 (Filed With SEC on March 29, 2019)
Purchase Agreement between the Company and the Purchasers, dated March 26, 2019 (Filed With SEC on March 29, 2019)
Form of Pre-Funded Warrant (Filed With SEC on March 29, 2019)
Amendment No. 10 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated October 15, 2018 (Filed With SEC on March 7, 2019)